Home » Newsletters » BioWorld Science

BioWorld Science

June 26, 2006

View Archived Issues

Istradefylline shows potential in restless legs syndrome

XP-13512 improves restless legs syndrome symptoms in polysomnography trial

Transgene and NCI sign melanoma CRADA letter of intent

Enrollment completed in study of DAC:GRF for HIV-associated lipodystrophy

Affibody and GE Healthcare enter research agreement

PharmaGap seeks to outlicense or sell PhG-alpha1

Positive findings in European study of Repel-CV

Corgentech changes name to Anesiva

Enrollment open in phase IIa study of NCX-1000 in portal hypertension

Phase I study of CR011-vcMMAE for melanoma commences

Preclinical findings for Mymetics' HIV-AIDS prophylactic vaccine candidate

Desonate NDA accepted for filing

Compound Therapeutics changes name to Adnexus Therapeutics

Bone loss treatment ACE-011 enters phase I

Clearance for phase I/II trial protocol of AMZ-0026 in HIV patients

Phase I study cleared to begin for CT-322 in cancer

DG-041 begins phase II program for peripheral artery disease

AA-4500 highly effective in treatment of Dupuytren's contracture

bPiDDB blocks nicotine-induced dopamine release in the nucleus accumbens

Novel human anticocaine monoclonal antibody limits cocaine distribution to the brain

FDA approval for extended- and immediate-release oxymorphone hydrochloride

Accelerated approval for Prezista in HIV combination therapy

Lumigan approved for first-line use

Recent patents describe novel therapeutic agents for atopic dermatitis, psoriasis

Novel treatments for inflammatory disorders claimed in recent patents

Recent patents disclose new therapeutic agents for psychological disorders

Fenofibrate/metformin combination effective in patients with metabolic syndrome

Extract from Artemisia dracunculus shows promising antidiabetic properties

Favorable pharmacokinetic profile of apricitabine in healthy subjects

Novel topoisomerase II inhibitor shows potent antitumor activity in vivo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...